menu
    • menu

    Find Bimatoprost manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 22
    Cayman Bimatoprost

    Virtual Booth

    Contact Supplier

    Chiogate Bimatoprost

    Virtual Booth

    Contact Supplier

    Bimatoprost

    Virtual Booth

    Contact Supplier

    Bimatoprost

    Virtual Booth

    Contact Supplier

    EuroAPI Bimatoprost

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 155206-00-1, Lumigan, Latisse, Agn 192024, Prostamide, Agn-192024
    Molecular Formula
    C25H37NO4
    Molecular Weight
    415.6  g/mol
    InChI Key
    AQOKCDNYWBIDND-FTOWTWDKSA-N
    FDA UNII
    QXS94885MZ
    Bimatoprost
    A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
    Bimatoprost is a Prostaglandin Analog.
    1 2D Structure

    Bimatoprost

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
    2.1.2 InChI
    InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
    2.1.3 InChI Key
    AQOKCDNYWBIDND-FTOWTWDKSA-N
    2.1.4 Canonical SMILES
    CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O
    2.1.5 Isomeric SMILES
    CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
    2.2 Other Identifiers
    2.2.1 UNII
    QXS94885MZ
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 192024, Agn

    2. Agn 192024

    3. Latisse

    4. Lumigan

    2.3.2 Depositor-Supplied Synonyms

    1. 155206-00-1

    2. Lumigan

    3. Latisse

    4. Agn 192024

    5. Prostamide

    6. Agn-192024

    7. (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-n-ethylhept-5-enamide

    8. Qxs94885mz

    9. (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-5-heptenamide

    10. Chebi:51230

    11. (e)-7-[3,5-dihydroxy-2-[(e)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-n-ethylhept-5-enamide

    12. Bimatoprostum

    13. Unii-qxs94885mz

    14. (5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-n-ethylhept-5-enamide

    15. (5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl}-n-ethylhept-5-enamide

    16. Lumigan (tn)

    17. (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((s,e)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-n-ethylhept-5-enamide

    18. (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-n-ethylhept-5-enamide

    19. Bimatoprost [usan:inn:ban:jan]

    20. Bimatoprost In Bulk

    21. Latisse (tn)

    22. Durysta

    23. Ls-181817

    24. Bimatoprost [mi]

    25. Bimatoprost [inn]

    26. Bimatoprost [jan]

    27. (5z)-bimatoprost

    28. Bimatoprost [inci]

    29. Bimatoprost [usan]

    30. Bimatoprost [vandf]

    31. Bimatoprost [mart.]

    32. Schembl24425

    33. Bimatoprost [who-dd]

    34. 5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-(1alpha(z),2beta(1e,3s*),3alpha,5alpha))-

    35. Mls006010039

    36. Us9271961, Bimatoprost

    37. Bimatoprost (jan/usan/inn)

    38. Bimatoprost [ema Epar]

    39. Gtpl1958

    40. Chembl1200963

    41. Bimatoprost [orange Book]

    42. Dtxsid30895042

    43. Bdbm220120

    44. Ex-a1769

    45. Ganfort Component Bimatoprost

    46. Hy-b0191

    47. Zinc4474405

    48. Mfcd03411999

    49. Akos015995566

    50. Am84507

    51. Bimatoprost Component Of Ganfort

    52. Db00905

    53. Fd10460

    54. Ncgc00181745-01

    55. Ncgc00181745-03

    56. 5-heptenamide, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (5z)-

    57. 5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-1(alpha(z),2beta(1e,3s*)3alpha,5alpha))-

    58. As-35082

    59. Smr000058996

    60. B6165

    61. D02724

    62. 206b001

    63. Sr-01000942224

    64. Q2393348

    65. Sr-01000942224-1

    66. 17-phenyl Trinor Prostaglandin F2alpha Ethyl Amide

    67. 17-phenyl-tri-norprostaglandin F2alpha-ethyl Amide, >=95%, Solid

    68. 15m

    69. 5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-1(.alpha.(z),2.beta.(1e,3s*)3.alpha.,5.alpha.))-

    70. 5-heptenamide, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-n-ethyl-, (5z)-

    2.4 Create Date
    2005-12-16
    3 Chemical and Physical Properties
    Molecular Weight 415.6 g/mol
    Molecular Formula C25H37NO4
    XLogP32.8
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count12
    Exact Mass415.27225866 g/mol
    Monoisotopic Mass415.27225866 g/mol
    Topological Polar Surface Area89.8 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity541
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count2
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 6  
    Drug NameBimatoprost
    PubMed HealthBimatoprost (Into the eye)
    Drug ClassesAntiglaucoma, Ophthalmologic Agent
    Drug LabelLATISSE (bimatoprost ophthalmic solution) 0.03% is a synthetic prostaglandin analog. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide, and its molecular weight is 41...
    Active IngredientBimatoprost
    Dosage FormSolution
    Routeophthalmic
    Strength0.01%; 0.03%; 0.03
    Market StatusTentative Approval
    CompanyApotex; Sandoz

    2 of 6  
    Drug NameLatisse
    PubMed HealthBimatoprost (Into the eye)
    Drug ClassesAntiglaucoma, Ophthalmologic Agent
    Drug LabelLATISSE (bimatoprost ophthalmic solution) 0.03% is a synthetic prostaglandin analog. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide, and its molecular weight is 41...
    Active IngredientBimatoprost
    Dosage FormSolution/drops
    RouteTopical
    Strength0.03%
    Market StatusPrescription
    CompanyAllergan

    3 of 6  
    Drug NameLumigan
    Drug LabelLUMIGAN 0.01% and 0.03% (bimatoprost ophthalmic solution) is a synthetic prostamide analog with ocular hypotensive activity. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5-N-ethylhept...
    Active IngredientBimatoprost
    Dosage FormSolution/drops
    RouteOphthalmic
    Strength0.01%
    Market StatusPrescription
    CompanyAllergan

    4 of 6  
    Drug NameBimatoprost
    PubMed HealthBimatoprost (Into the eye)
    Drug ClassesAntiglaucoma, Ophthalmologic Agent
    Drug LabelLATISSE (bimatoprost ophthalmic solution) 0.03% is a synthetic prostaglandin analog. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide, and its molecular weight is 41...
    Active IngredientBimatoprost
    Dosage FormSolution
    Routeophthalmic
    Strength0.01%; 0.03%; 0.03
    Market StatusTentative Approval
    CompanyApotex; Sandoz

    5 of 6  
    Drug NameLatisse
    PubMed HealthBimatoprost (Into the eye)
    Drug ClassesAntiglaucoma, Ophthalmologic Agent
    Drug LabelLATISSE (bimatoprost ophthalmic solution) 0.03% is a synthetic prostaglandin analog. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide, and its molecular weight is 41...
    Active IngredientBimatoprost
    Dosage FormSolution/drops
    RouteTopical
    Strength0.03%
    Market StatusPrescription
    CompanyAllergan

    6 of 6  
    Drug NameLumigan
    Drug LabelLUMIGAN 0.01% and 0.03% (bimatoprost ophthalmic solution) is a synthetic prostamide analog with ocular hypotensive activity. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5-N-ethylhept...
    Active IngredientBimatoprost
    Dosage FormSolution/drops
    RouteOphthalmic
    Strength0.01%
    Market StatusPrescription
    CompanyAllergan

    4.2 Drug Indication

    Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments. Bimatoprost is also indicated to treat eyelash hypotrichosis.

    Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

    Treatment of glaucoma, Treatment of non-scarring hair loss

    Treatment of androgenic alopecia

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment. Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Bimatoprost rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes. Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness. Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.

    5.2 MeSH Pharmacological Classification

    Antihypertensive Agents

    Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    BIMATOPROST
    5.3.2 FDA UNII
    QXS94885MZ
    5.3.3 Pharmacological Classes
    Prostaglandins [CS]; Prostaglandin Analog [EPC]
    5.4 ATC Code

    S01EE03

    S - Sensory organs

    S01 - Ophthalmologicals

    S01E - Antiglaucoma preparations and miotics

    S01EE - Prostaglandin analogues

    S01EE03 - Bimatoprost

    5.5 Absorption, Distribution and Excretion

    Absorption

    This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study. By 10 minutes, peak blood concentration was achieved. Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing. One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Bimatoprost effects may last up to 24 hours.

    Route of Elimination

    One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.

    Volume of Distribution

    The volume of distribution at steady state is 0.67 L/kg.. It penetrates the human cornea and sclera.

    Clearance

    The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.

    5.6 Metabolism/Metabolites

    Bimatoprost is hydrolyzed to its active form, bimatoprost acid, in the eye. Bimatoprost undergoes oxidation, N-deethylation, and glucuronidation after it is systemically absorbed, and this leads to the production of various metabolites. In vitro studies show that CYP3A4 is an enzyme that participates in the metabolism of bimatoprost. Despite this, many enzymes and pathways metabolize bimatoprost, therefore, no significant drug-drug interactions are likely to occur. Glucuronidated metabolites comprise most of the excreted drug product in the blood, urine, and feces in rats.

    5.7 Biological Half-Life

    The elimination half-life of bimatoprost is approximately 45 minutes.

    5.8 Mechanism of Action

    Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2. Bimatoprost mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. Bimatoprost does not affect aqueous humor production.

    JDMF

    read-more
    read-moreread-more

    01

    EUROAPI Hungary Ltd.

    France
    arrow
    TIDES USA
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    Registration Number : 229MF10098

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2017-05-24

    Latest Date of Registration : 2017-05-24

    EUROAPI Compnay Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Everlight Chemical Industrial Corpo...

    Taiwan
    PCC
    Not Confirmed
    arrow

    Everlight Chemical Industrial Corpo...

    Taiwan
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Taiwan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    Registration Number : 228MF10186

    Registrant's Address : 6Floor, Chung Ting Building No. 77, Section 2, Tun Hua South Road, Taipei, Taiwan

    Initial Date of Registration : 2016-09-20

    Latest Date of Registration : 2017-07-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Kyowa Pharma Chemical Co., Ltd.

    Japan
    PCC
    Not Confirmed
    arrow

    Kyowa Pharma Chemical Co., Ltd.

    Japan
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost (for manufacturing purposes only)

    Registration Number : 224MF10081

    Registrant's Address : 530 Chokeiji, Takaoka City, Toyama Prefecture

    Initial Date of Registration : 2012-04-13

    Latest Date of Registration : 2023-02-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Piramal Healthcare (Canada) Limited

    India
    PCC
    Not Confirmed
    arrow

    Piramal Healthcare (Canada) Limited

    India
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    Registration Number : 220MF10035

    Registrant's Address : 110 Industrial Parkway North, Aurora, Ontario L4G 3H4 Canada

    Initial Date of Registration : 2008-02-05

    Latest Date of Registration : 2009-12-22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    YS Life Science Co. , Ltd.

    South Korea
    PCC
    Not Confirmed
    arrow

    YS Life Science Co. , Ltd.

    South Korea
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost "For manufacturing purposes only"

    Registration Number : 229MF10152

    Registrant's Address : 207, Sujeong-ro, Jangan-myeon, Manse-gu, Hwaseong-si, Gyeonggi-do, 18581, Republic of...

    Initial Date of Registration : 2017-08-04

    Latest Date of Registration : 2017-08-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Cayman Pharma s.r.o

    Czech Republic
    arrow
    Chemspec Europe
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

    Contact Supplier Contact Supplier
    Flag Czech Republic
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Cayman Pharma is a leading European provider of cGMP prostaglandin APIs, created in 2006 from the merger of Cayman Chemical and NeraPharm, combining deep prostaglandin chemistry ex...

    Cayman Pharma is a leading European provider of cGMP prostaglandin APIs, created in 2006 from the merger of Cayman Chemical and NeraPharm, combining deep prostaglandin chemistry expertise. With nearly 60 years of experience, it uses a patented route for the prostaglandin core structure and holds GMP approvals from European and US regulators. The company supports fertility, eye care, glaucoma, and pulmonary hypertension products with validated GMP routes and regulatory support. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Cayman

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Inke S.A

    Spain
    arrow
    RDD
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothInke S.A: APIs manufacturing plant.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...

    Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse therapeutic areas, but mainly for use in Respiratory. Inke has been successfully inspected by every major global authority for a wide array of products (last inspection on behalf of US-FDA was in 2023). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Inke Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Chirogate International

    Taiwan
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothChirogate is a professional Prostaglandin manufacturer.

    Contact Supplier Contact Supplier
    Flag Taiwan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Chirogate, established in 1999, is a leading supplier of niche-market molecules, specializing in prostaglandins. Focused on quality and compliance, it offers competitively priced p...

    Chirogate, established in 1999, is a leading supplier of niche-market molecules, specializing in prostaglandins. Focused on quality and compliance, it offers competitively priced prostaglandin APIs to regulated and unregulated markets worldwide. Using proprietary processes and advanced technology, Chirogate adheres to cGMP and international manufacturing standards, ensuring product safety and quality. The company has passed successful regulatory inspections, including by the USFDA. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Chirogate CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    EUROAPI

    France
    arrow
    TIDES USA
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : EUROAPI focuses on reinventing active ingredient solutions to sustainably meet the needs of customers and patients worldwide. The company is a leading API player with a portfolio o...

    EUROAPI focuses on reinventing active ingredient solutions to sustainably meet the needs of customers and patients worldwide. The company is a leading API player with a portfolio of around 200 products, covering a wide range of technologies and innovative molecules through CDMO activities. Supported by 3,650 employees, strong R&D capabilities, and six manufacturing sites in Europe, EUROAPI delivers high-quality API manufacturing to customers in more than 80 countries. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    EUROAPI Compnay Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Century Pharmaceuticals

    India
    arrow
    Vietnam Medi-Pharm Expo
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Century Pharmaceuticals, established in 1982, has 40 years of experience manufacturing APIs for major pharma companies in India and abroad. Its products are made in compliance with...

    Century Pharmaceuticals, established in 1982, has 40 years of experience manufacturing APIs for major pharma companies in India and abroad. Its products are made in compliance with cGMP, 21 CFR, and ICH guidelines, and it also produces intermediates and develops new APIs as per client requirements. The company conducts biotechnological research on human therapeutic proteins, including treatments for asthma, mastocytosis, and basophilic leukemia, and supplies research-grade biotech and animal health products. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Century Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Transo-Pharm USA LLC

    U.S.A
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...

    Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and acts as a sourcing and regulatory marketing agent for API manufacturers. Transo-Pharm assists with DMF setup, GMP consulting, and regulatory activities, supported by a regulatory team, warehouse facilities, proprietary API process IPs, and laboratory partnerships, with offices in Shanghai, Hong Kong, Singapore, and the US. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Transo Pharm USA Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    LGM Pharma

    U.S.A
    arrow
    CPhI North America
    Booth #730
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

    LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Jai Radhe Sales

    India
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...

    Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and regulatory support, and strives for global standards. Known for quality and affordability, it has established a niche through innovative methods and exports to nearly every continent. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Jai Radhe Sales

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    HRV Pharma

    India
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...

    HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing, manufacturing, and supply services to support partners entering new markets worldwide. HRV Pharma works closely with major pharma and food additive companies and represents over 30 Indian drugmakers, primarily serving Europe, the US, and the Middle East. Headquartered in India, it operates offices in the US, Switzerland, Dubai, Lithuania, and Turkey. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    HRV Global Life Sciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Capital Farma

    Spain
    arrow
    CDMO Live Europe 2026
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCapital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bimatoprost

    About the Company : Capital Farma provides integrated pharmaceutical solutions with a focus on high-quality Active Pharmaceutical Ingredients (APIs) sourced from leading European manufacturers. The co...

    Capital Farma provides integrated pharmaceutical solutions with a focus on high-quality Active Pharmaceutical Ingredients (APIs) sourced from leading European manufacturers. The company co-develops proprietary APIs with established European Contract Manufacturing Organizations (CMOs) and offers complete product packages by combining APIs with Finished Dosage Form (FDF) dossiers. Capital Farma also supports market expansion through FDF licensing services, enabling partners to access new regions efficiently. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Capital Farma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Parenteral

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 155206-00-1 / Bimatoprost API manufacturers, exporters & distributors?

    Bimatoprost manufacturers, exporters & distributors 1

    87

    PharmaCompass offers a list of Bimatoprost API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Bimatoprost manufacturer or Bimatoprost supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bimatoprost manufacturer or Bimatoprost supplier.

    API | Excipient name

    Bimatoprost

    Synonyms

    155206-00-1, Lumigan, Latisse, Agn 192024, Prostamide, Agn-192024

    Cas Number

    155206-00-1

    Unique Ingredient Identifier (UNII)

    QXS94885MZ

    About Bimatoprost

    A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

    Lumigan (TN) Manufacturers

    A Lumigan (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lumigan (TN), including repackagers and relabelers. The FDA regulates Lumigan (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lumigan (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Lumigan (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Lumigan (TN) Suppliers

    A Lumigan (TN) supplier is an individual or a company that provides Lumigan (TN) active pharmaceutical ingredient (API) or Lumigan (TN) finished formulations upon request. The Lumigan (TN) suppliers may include Lumigan (TN) API manufacturers, exporters, distributors and traders.

    click here to find a list of Lumigan (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Lumigan (TN) USDMF

    A Lumigan (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Lumigan (TN) active pharmaceutical ingredient (API) in detail. Different forms of Lumigan (TN) DMFs exist exist since differing nations have different regulations, such as Lumigan (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Lumigan (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Lumigan (TN) USDMF includes data on Lumigan (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lumigan (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Lumigan (TN) suppliers with USDMF on PharmaCompass.

    Lumigan (TN) JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Lumigan (TN) Drug Master File in Japan (Lumigan (TN) JDMF) empowers Lumigan (TN) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Lumigan (TN) JDMF during the approval evaluation for pharmaceutical products. At the time of Lumigan (TN) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Lumigan (TN) suppliers with JDMF on PharmaCompass.

    Lumigan (TN) KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Lumigan (TN) Drug Master File in Korea (Lumigan (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lumigan (TN). The MFDS reviews the Lumigan (TN) KDMF as part of the drug registration process and uses the information provided in the Lumigan (TN) KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Lumigan (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lumigan (TN) API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Lumigan (TN) suppliers with KDMF on PharmaCompass.

    Lumigan (TN) WC

    A Lumigan (TN) written confirmation (Lumigan (TN) WC) is an official document issued by a regulatory agency to a Lumigan (TN) manufacturer, verifying that the manufacturing facility of a Lumigan (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lumigan (TN) APIs or Lumigan (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Lumigan (TN) WC (written confirmation) as part of the regulatory process.

    click here to find a list of Lumigan (TN) suppliers with Written Confirmation (WC) on PharmaCompass.

    Lumigan (TN) NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lumigan (TN) as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Lumigan (TN) API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Lumigan (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Lumigan (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lumigan (TN) NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Lumigan (TN) suppliers with NDC on PharmaCompass.

    Lumigan (TN) GMP

    Lumigan (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Lumigan (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lumigan (TN) GMP manufacturer or Lumigan (TN) GMP API supplier for your needs.

    Lumigan (TN) CoA

    A Lumigan (TN) CoA (Certificate of Analysis) is a formal document that attests to Lumigan (TN)'s compliance with Lumigan (TN) specifications and serves as a tool for batch-level quality control.

    Lumigan (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Lumigan (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Lumigan (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Lumigan (TN) EP), Lumigan (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lumigan (TN) USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search